ACRO Biomedical (6748) 주식 개요아크로바이오메디컬은 의료용 재생 바이오 소재를 개발하는 기업입니다. 자세히 보기6748 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석지난 5년간 매년 수익이 8.7% 감소했습니다.의미 있는 수익이 없습니다(NT$38M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기6748 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$69.003.1k% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-83m86m2016201920222025202620282031Revenue NT$86.1mEarnings NT$15.6mAdvancedSet Fair ValueView all narrativesACRO Biomedical Co., Ltd. 경쟁사Pharmosa BiopharmSymbol: TPEX:6875Market cap: NT$4.9bMycenax BiotechSymbol: TPEX:4726Market cap: NT$5.9bSenhwa BiosciencesSymbol: TPEX:6492Market cap: NT$4.1bStemCyte InternationalSymbol: TWSE:4178Market cap: NT$4.1b가격 이력 및 성과ACRO Biomedical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NT$69.0052주 최고가NT$94.3052주 최저가NT$33.85베타0.411개월 변동-4.30%3개월 변동n/a1년 변동84.49%3년 변동165.38%5년 변동n/aIPO 이후 변동77.15%최근 뉴스 및 업데이트New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).공시 • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).공시 • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.더 많은 업데이트 보기Recent updatesNew Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).공시 • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).공시 • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Mar 28ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanNew Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.17b market cap, or US$65.9m).New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$1.55b market cap, or US$47.5m).New Risk • Apr 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$1.61b market cap, or US$49.5m).공시 • Apr 04ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024.New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$2.37b market cap, or US$75.5m).New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.14b market cap, or US$67.7m).New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$1.65b market cap, or US$53.1m).공시 • Apr 10ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022.주주 수익률6748TW BiotechsTW 시장7D0%-1.3%2.6%1Y84.5%28.2%94.7%전체 주주 수익률 보기수익률 대 산업: 6748은 지난 1년 동안 28.2%의 수익을 기록한 TW Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 6748은 지난 1년 동안 94.7%를 기록한 TW 시장보다 저조한 성과를 냈습니다.주가 변동성Is 6748's price volatile compared to industry and market?6748 volatility6748 Average Weekly Movement6.3%Biotechs Industry Average Movement6.0%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%안정적인 주가: 6748는 지난 3개월 동안 TW 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 6748의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2014n/aDar-Jen Hsiehwww.acrobiomedical.com아크로바이오메디칼은 의료용 재생 바이오 소재를 개발하는 회사입니다. 이 회사는 상처 치료, 정형외과, 치과, 안과, 미용 미세 성형 수술, 미용 및 안과, 조직 공학 및 재생 의약품 분야의 제품을 제공합니다. 2014년 설립되었으며 대만 가오슝에 본사를 두고 있습니다.더 보기ACRO Biomedical Co., Ltd. 기초 지표 요약ACRO Biomedical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?6748 기초 통계시가총액NT$4.91b순이익 (TTM)-NT$82.65m매출 (TTM)NT$38.26m128.5x주가매출비율(P/S)-59.5x주가수익비율(P/E)6748는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표6748 손익계산서 (TTM)매출NT$38.26m매출원가NT$19.73m총이익NT$18.53m기타 비용NT$101.18m순이익-NT$82.65m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-1.16총이익률48.43%순이익률-216.06%부채/자본 비율0%6748의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 20:48종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ACRO Biomedical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).
공시 • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
공시 • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.
Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).
공시 • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
공시 • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.
Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Mar 28ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.17b market cap, or US$65.9m).
New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$1.55b market cap, or US$47.5m).
New Risk • Apr 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$1.61b market cap, or US$49.5m).
공시 • Apr 04ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024.
New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$2.37b market cap, or US$75.5m).
New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.14b market cap, or US$67.7m).
New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$1.65b market cap, or US$53.1m).
공시 • Apr 10ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022.
